Results 241 to 250 of about 1,319,691 (347)
#1091 Progression of cardiac remodelling and dysfunction is accompanied by altered metabolic profile in chronic kidney disease [PDF]
Juliana H. Boukhaled +11 more
openalex +1 more source
This work offers unique Ginger‐based 3D‐printable resins that can print customizable high‐resolution complex designs. The customizable printing backbone of Zingerol prints also mimics various human bones' strength. Acquisition of in‐vivo biocompatibility in rat model with no severe inflammatory response, along with in‐vitro antioxidant and ex‐vivo anti‐
Simran Jindal +9 more
wiley +1 more source
Finerenone in Patients with Nondiabetic Chronic Kidney Disease-A Retrospective Study. [PDF]
Albakr RB +5 more
europepmc +1 more source
The lipid droplet inhibitor (LDI), templated with large‐pore mesoporous silica and functionalized with PKCα C1A and lipase, targets lipid degradation in fatty liver. The LDI maintains stable association with lipid droplets, thereby suppressing their formation and expansion.
Seunghee Kim +12 more
wiley +1 more source
International variations in chronic kidney disease patients' pain experience and its management. [PDF]
Raina R +12 more
europepmc +1 more source
The Space Within: How Architected Voids Promote Tissue Formation
This review explores the role of void spaces in tissue engineering scaffolds and examines four key methods for introducing porosity into hydrogels at different scales. It discusses sacrificial templating, microgels, phase separation, and 3D printing, highlighting principles, advantages, and limitations. It also addresses emerging strategies integrating
Anna Puiggalí‐Jou +3 more
wiley +1 more source
Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease. [PDF]
Rusu M +4 more
europepmc +1 more source
Outcomes of Diabetic Tractional Retinal Detachments in Patients with Chronic Kidney Disease
Lekha Mukkamala +2 more
openalex +1 more source
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa +3 more
wiley +1 more source

